Comming from Biodonostia Health Research Institute and University of the Basque Country, the company aim is to develop new drugs “First in Class” based on the interaction with new protein receptor that modulates the ryanodine calcium channel.
Comming from Biodonostia Health Research Institute and University of the Basque Country, the company aim is to develop new drugs “First in Class” based on the interaction with new protein receptor that modulates the ryanodine calcium channel.
The company is headed by a first-rate team with experience in drug development, neuromuscular diseases, venture capital and licensing.
Our advisors are renowned scientists in the world of medical chemistry and entrepreneurs with a long history working and advising the main players in pharmaceutical companies.
The company is headed by a first-rate team with experience in drug development, neuromuscular diseases, venture capital and licensing.
Our advisors are renowned scientists in the world of medical chemistry and entrepreneurs with a long history working and advising the main players in pharmaceutical companies.
Av. Tolosa 72
20018 y Donostia/ San Sebastián
Spain